PKD Cures Act
The source supplies the latest action, but no lifecycle stage.
Latest action (4 Jun 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
The bill, titled the "PKD Cures Act," would direct the National Institutes of Health (NIH) to expand and intensify research on polycystic kidney disease (PKD). This includes supporting basic, translational, and clinical research to understand the disease, identify potential treatments, and evaluate new therapies. The NIH would also be required to foster collaboration with other entities and support training for PKD researchers.
The bill aims to address PKD, a genetic disease affecting many Americans and leading to kidney failure, dialysis, and transplantation. It would also establish a working group to create a comprehensive roadmap for PKD research and innovation. This group would identify research priorities, suggest strategies for public-private collaboration, and propose timelines for advancements, reporting its findings to Congress.
As an introduced bill, H.R. 9169 has been referred to the House Committee on Energy and Commerce. It would need to be considered and passed by the committee, then by the full House of Representatives, and subsequently by the Senate before it could be sent to the President to become law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
4 Jun 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 9169 do?
- The bill, titled the "PKD Cures Act," would direct the National Institutes of Health (NIH) to expand and intensify research on polycystic kidney disease (PKD). This includes supporting basic, translational, and clinical research to understand the disease, identify potential treatments, and evaluate new therapies. The NIH would also be required to foster collaboration with other entities and support training for PKD researchers. The bill aims to address PKD, a genetic disease affecting many Americans and leading to kidney failure, dialysis, and transplantation. It would also establish a working group to create a comprehensive roadmap for PKD research and innovation. This group would identify research priorities, suggest strategies for public-private collaboration, and propose timelines for advancements, reporting its findings to Congress. As an introduced bill, H.R. 9169 has been referred to the House Committee on Energy and Commerce. It would need to be considered and passed by the committee, then by the full House of Representatives, and subsequently by the Senate before it could be sent to the President to become law.
- Has H.R. 9169 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 9169. Check the latest action and official source below.
- Who sponsored H.R. 9169?
- H.R. 9169 was sponsored by Rep. Wasserman Schultz, Debbie [D-FL-25] (D-FL), with 7 cosponsors.
- What's the latest action on H.R. 9169?
- Referred to the House Committee on Energy and Commerce. (4 Jun 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Wasserman Schultz, Debbie [D-FL-25]
RAISE Act of 2026
PROTECT Act
Build Homes, Not Hate Act of 2026
No PREJUDICE Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.